Treating HCV in Patients with HCC | August 19, 2026
Date of Presentation: August 19, 2026
Type: Past Presentation
Audience: Clinical
Program: Hepatitis C
Keywords: #cancer #carcinoma #hcc #hcv #hepatitis #hepatocellular #liver #management
In this presentation, Dr. Deming reviews the critical, bidirectional relationship between Hepatitis C Virus (HCV) infection and hepatocellular carcinoma (HCC). Participants will examine how achieving a sustained virologic response (SVR) reduces both primary cancer risks and post-treatment recurrence rates. Dr. Deming also analyzes how active malignancies impact HCV treatment success and provides evidence-based strategies to optimize antiviral therapy for patients with early-stage HCC and complex care decisions.
Recording:
Presented by:
Dr. Paulina Deming
Dr. Paulina Deming is an Associate Professor-Clinical Educator within the Pharmacy Practice and Administrative Sciences Department at the College of Pharmacy at the University of New Mexico Health Sciences Center (UNMHSC). Dr. Deming completed a general practice residency and infectious diseases pharmacotherapy residency at UNMHSC. Her interests are focused in hepatitis C virus (HCV) infections and clinical therapeutics. She is the assistant director for the Project ECHO (Extension for Community Healthcare Outcomes) HCV clinic and serves on Project ECHO’s expert faculty panel advising providers on HCV care in community, corrections, and within the Indian Health Services settings. Licensed as a pharmacist clinician, she sees patients through the UNMHSC’s HCV clinic and the Truman HCV-HIV coinfection clinic. In addition to teaching and clinical work, Dr. Deming has co-authored papers on the management of HCV infections as well as HCV treatment outcomes in real-world settings.
Read the full bio …Resources Provided:
Date added: August 14, 2026
